Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Metabolism and One-Carbon Pathway Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SHMT2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SHMT2 Recombinant Protein (Active Tetramer Spec) High purity (>95%), Endotoxin Controlled, Sequence Verified. Suitable for enzymatic and biophysical binding assays. |
View SHMT2 Products |
| Gene Delivery | SHMT2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and target overexpression studies. |
View SHMT2 Products |
| Benchmark Ab | Anti-SHMT2 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and cellular localization assays. |
View SHMT2 Products |
| Validator | SHMT2 siRNA Set For knockdown verification and target specificity validation in phenotypic assays. |
View SHMT2 Products |
| Related Target A | SHMT1 Cytosolic isoform sharing high sequence homology. Crucial for selectivity counter-screening to avoid off-target toxicity. |
View SHMT1 Products |
| Related Target B | MTHFD2 Mitochondrial one-carbon pathway partner. Synergistic target highly co-expressed with SHMT2 in tumor cells. |
View MTHFD2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (SHMT2 vs. SHMT1) | Both human SHMT1 and SHMT2 recombinant proteins available with strictly verified sequences and high purity (>95%) for side-by-side screening. |
| Mitochondrial Enzyme Conformation | Expression systems optimized for soluble, properly folded oligomeric states (active tetramer conformation) to ensure physiological relevance. |
| Lack of Controls | Validated benchmark antibodies and reference inhibitors available to establish assay baselines. |
| False Positives in Cellular Assays | Sequence-specific siRNA pool included to confirm that small molecule phenotypic effects are driven by SHMT2 depletion. |
Live SHMT2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SHMT2 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum metabolic inhibitors to highly selective, small-molecule allosteric inhibitors. As first-generation therapies reach preclinical validation and early clinical phases, the next wave of R&D is targeting the metabolic plasticity of solid tumors, specifically addressing resistance bypass pathways in one-carbon metabolism.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Servier (Agios), Academic Spin-offs | Lymphoma, Glioma, Colorectal Cancer | Selectivity Assay (Need highly purified SHMT1 and SHMT2 proteins for comparative enzymatic profiling) |
| Allosteric Modulators | Biotech Consortia | Solid Tumors (Hypoxic microenvironments) | Biophysical Binding Assays (Need sequence-verified, natively folded tetrameric proteins) |
| Combination Therapies | Oncology Research Institutes | Drug-resistant Solid Tumors | Target Knockdown Verification (Need high-potency siRNA and Lentivirus for pathway validation) |